Dynavax Received, Rejected Buyout Offer From Undisclosed Bidder - Update

Dow Jones

01/13

By Kelly Cloonan

Dynavax received a competing takeover offer from an undisclosed, publicly-traded biotechnology company before striking a deal with Sanofi.

The unsolicited, non-binding proposal from Dec. 23 valued Dynavax's shares at $15 apiece in cash, the vaccine specialist disclosed in a filing Monday. The company didn't disclose the name of the bidder.

The bidder continued to express interest in Dynavax on Dec. 28, several days after Dynavax and Sanofi announced their deal, according to the filing. Sanofi's offer values Dynavax's shares at $15.50 apiece in cash.

Dynavax said its board determined the undisclosed bidder's offer was unlikely to lead to a superior proposal to Sanofi's bid. There was substantial risk of Sanofi withdrawing from discussions and Dynavax losing the company's final offer if it continued to pursue a higher price or delayed the execution of the merger agreement, Dynavax said.

The deal for the Emeryville, Calif., company marks Sanofi's fifth acquisition this year. Sanofi has turned to dealmaking to freshen up its lineup of medicines and vaccines after some of its experimental drugs hit snags in clinical studies or approval processes. Dynavax brings a Food and Drug Administration-approved hepatitis B shot, a candidate for a shingles vaccine and several other projects in development.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

January 12, 2026 15:23 ET (20:23 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2603525687"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603525687\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603525687?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 04:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603525687","market":"hk","top_or_hot":-1,"title":"Dynavax Received, Rejected Buyout Offer From Undisclosed Bidder - Update","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Dynavax received a competing takeover offer from an undisclosed, publicly-traded biotechnology company before striking a deal with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>. \n</p>\n<p>\n  The unsolicited, non-binding proposal from Dec. 23 valued Dynavax's shares at $15 apiece in cash, the vaccine specialist disclosed in a filing Monday. The company didn't disclose the name of the bidder. \n</p>\n<p>\n  The bidder continued to express interest in Dynavax on Dec. 28, several days after Dynavax and <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> announced their deal, according to the filing. Sanofi's offer values Dynavax's shares at $15.50 apiece in cash. \n</p>\n<p>\n  Dynavax said its board determined the undisclosed bidder's offer was unlikely to lead to a superior proposal to Sanofi's bid. There was substantial risk of Sanofi withdrawing from discussions and Dynavax losing the company's final offer if it continued to pursue a higher price or delayed the execution of the merger agreement, Dynavax said. \n</p>\n<p>\n  The deal for the Emeryville, Calif., company marks Sanofi's fifth acquisition this year. Sanofi has turned to dealmaking to freshen up its lineup of medicines and vaccines after some of its experimental drugs hit snags in clinical studies or approval processes. Dynavax brings a Food and Drug Administration-approved hepatitis B shot, a candidate for a shingles vaccine and several other projects in development. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 15:23 ET (20:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dynavax Received, Rejected Buyout Offer From Undisclosed Bidder - Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDynavax Received, Rejected Buyout Offer From Undisclosed Bidder - Update\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-01-13 04:23</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Dynavax received a competing takeover offer from an undisclosed, publicly-traded biotechnology company before striking a deal with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>. \n</p>\n<p>\n  The unsolicited, non-binding proposal from Dec. 23 valued Dynavax's shares at $15 apiece in cash, the vaccine specialist disclosed in a filing Monday. The company didn't disclose the name of the bidder. \n</p>\n<p>\n  The bidder continued to express interest in Dynavax on Dec. 28, several days after Dynavax and <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> announced their deal, according to the filing. Sanofi's offer values Dynavax's shares at $15.50 apiece in cash. \n</p>\n<p>\n  Dynavax said its board determined the undisclosed bidder's offer was unlikely to lead to a superior proposal to Sanofi's bid. There was substantial risk of Sanofi withdrawing from discussions and Dynavax losing the company's final offer if it continued to pursue a higher price or delayed the execution of the merger agreement, Dynavax said. \n</p>\n<p>\n  The deal for the Emeryville, Calif., company marks Sanofi's fifth acquisition this year. Sanofi has turned to dealmaking to freshen up its lineup of medicines and vaccines after some of its experimental drugs hit snags in clinical studies or approval processes. Dynavax brings a Food and Drug Administration-approved hepatitis B shot, a candidate for a shingles vaccine and several other projects in development. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 15:23 ET (20:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603525687","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603525687","pubTimestamp":1768249380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Dynavax received a competing takeover offer from an undisclosed, publicly-traded biotechnology company before striking a deal with Sanofi.The unsolicited, non-binding proposal from Dec. 23 valued Dynavax's shares at $15 apiece in cash, the vaccine specialist disclosed in a filing Monday. The company didn't disclose the name of the bidder.The bidder continued to express interest in Dynavax on Dec. 28, several days after Dynavax and Sanofi announced their deal, according to the filing. Sanofi's offer values Dynavax's shares at $15.50 apiece in cash.Dynavax said its board determined the undisclosed bidder's offer was unlikely to lead to a superior proposal to Sanofi's bid. There was substantial risk of Sanofi withdrawing from discussions and Dynavax losing the company's final offer if it continued to pursue a higher price or delayed the execution of the merger agreement, Dynavax said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","DVAX":"德纳维制药"},"translate_title":"Dynavax收到未公开投标人的收购要约并被拒绝-更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DVAX":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Dynavax received a competing takeover offer from an undisclosed, publicly-traded biotechnology company before striking a deal with Sanofi. \n\n\n  The unsolicited, non-binding proposal from Dec. 23 valued Dynavax's shares at $15 apiece in cash, the vaccine specialist disclosed in a filing Monday. The company didn't disclose the name of the bidder. \n\n\n  The bidder continued to express interest in Dynavax on Dec. 28, several days after Dynavax and Sanofi announced their deal, according to the filing. Sanofi's offer values Dynavax's shares at $15.50 apiece in cash. \n\n\n  Dynavax said its board determined the undisclosed bidder's offer was unlikely to lead to a superior proposal to Sanofi's bid. There was substantial risk of Sanofi withdrawing from discussions and Dynavax losing the company's final offer if it continued to pursue a higher price or delayed the execution of the merger agreement, Dynavax said. \n\n\n  The deal for the Emeryville, Calif., company marks Sanofi's fifth acquisition this year. Sanofi has turned to dealmaking to freshen up its lineup of medicines and vaccines after some of its experimental drugs hit snags in clinical studies or approval processes. Dynavax brings a Food and Drug Administration-approved hepatitis B shot, a candidate for a shingles vaccine and several other projects in development. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 12, 2026 15:23 ET (20:23 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}